Dermata Therapeutics (DRMA) Price & Analysis

Q: What was Dermata Therapeutics’s price range in the past 12 months?

Dermata Therapeutics lowest stock price was $5.73 and its highest was $30.74 in the past 12 months.

Q: What is Dermata Therapeutics’s market cap?

Dermata Therapeutics’s market cap is $41.14M.

Q: When is Dermata Therapeutics’s upcoming earnings report date?

Dermata Therapeutics’s upcoming earnings report date is Aug 07, 2025 which is tomorrow.

Q: How were Dermata Therapeutics’s earnings last quarter?

Dermata Therapeutics released its earnings results on May 14, 2025. The company reported -$4.5 earnings per share for the quarter, the consensus estimate of -$4.5 by $0.

Q: Is Dermata Therapeutics overvalued?

According to Wall Street analysts Dermata Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Dermata Therapeutics pay dividends?

Dermata Therapeutics does not currently pay dividends.

Q: What is Dermata Therapeutics’s EPS estimate?

Dermata Therapeutics’s EPS estimate is -2.9.

Q: How many shares outstanding does Dermata Therapeutics have?

Dermata Therapeutics has 6,378,118 shares outstanding.

Q: What happened to Dermata Therapeutics’s price movement after its last earnings report?

Dermata Therapeutics reported an EPS of -$4.5 in its last earnings report, expectations of -$4.5. Following the earnings report the stock price went down -0.128%.

Q: Which hedge fund is a major shareholder of Dermata Therapeutics?

Currently, no hedge funds are holding shares in DRMA

Compare

125 Followers

DRMA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.73 - $30.74

Previous CloseN/A

Volume28.34K

Average Volume (3M)18.34K

Market Cap

$41.14M

Enterprise Value-$4.15M

Total Cash (Recent Filing)$9.72M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.17

Next Earnings

Aug 07, 2025

EPS Estimate

-2.9

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.50

Shares Outstanding6,378,118

10 Day Avg. Volume26,427

30 Day Avg. Volume18,342

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)<0.01

Price to Sales (P/S)0.00

P/FCF Ratio-0.02

Enterprise Value/Market Cap-0.10

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda0.36

Forecast

1Y Price Target

$3.00

Price Target Upside-57.51% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsDRMA announced statistically significant positive topline data from STAR-1, its first pivotal Phase 3 trial of XYNGARI, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne.

Product AdherenceThe once-weekly application of XYNGARI is expected to improve patient compliance compared to daily FDA-approved topicals.

Technology And Market OpportunitiesThe unique Spongilla technology and promising clinical acne data present significant opportunities in acne, psoriasis, and aesthetic treatment markets.

Bears Say

Financial PositionThe company is pre-revenue and anticipates requiring a capital raise before the second Phase 3 clinical trial.

Share DilutionBased on expected share dilution from an anticipated capital raise, the 12-month price target is being lowered to $3.00, from $6.00.

Dermata Therapeutics News

Dermata Therapeutics Inc trading halted, news pending

19:50 EDT Dermata Therapeutics (DRMA) Inc trading halted, news pending Published first on TheFly – the ultimate source...

5d ago

DRMA

Dermata Therapeutics receives notice of grant of Australian patent

Dermata Therapeutics (DRMA) announced the Australian Patent Office has granted its patent application for its DMT410 program for...

29d ago

DRMA

Dermata Therapeutics Announces Reverse Stock Split

The latest update is out from Dermata Therapeutics ( ($DRMA) ). On July 30, 2025, Dermata Therapeutics announced...

7d ago

DRMA

Dermata Therapeutics Holds Annual Stockholders Meeting

The latest announcement is out from Dermata Therapeutics ( ($DRMA) ). On July 15, 2025, Dermata Therapeutics held...

21d ago

DRMA

Dermata Faces Nasdaq Delisting Risk, Plans Stock Split

Dermata Therapeutics ( ($DRMA) ) has issued an announcement. On May 14, 2025, Dermata Therapeutics received a letter...

30d ago

DRMA

Dermata Therapeutics Begins Manufacturing for STAR-2 Trial

Dermata Therapeutics ( ($DRMA) ) has provided an update. On May 20, 2025, Dermata Therapeutics announced the initiation...

3M ago

DRMA

Dermata Therapeutics price target lowered to $3 from $6 at Maxim

Maxim analyst Anthony Vendetti lowered the firm’s price target on Dermata Therapeutics (DRMA) to $3 from $6 and...

3M ago

DRMA

Dermata Faces Nasdaq Delisting Risk Over Bid Price

Dermata Therapeutics ( ($DRMA) ) has shared an announcement. On May 14, 2025, Dermata Therapeutics, Inc. announced that...

3M ago

DRMA

Dermata Reports Positive Phase 3 Trial Results

Dermata Therapeutics ( ($DRMA) ) just unveiled an update. In the first quarter of 2025, Dermata Therapeutics announced...

3M ago

DRMA

Dermata Therapeutics reports Q1 EPS (45c) vs. ($7.06) last year

“It was an exciting quarter for our team to announce positive topline results of the XYNGARI Phase 3...

3M ago

DRMA

Dermata Therapeutics sees cash runway into 1Q26

As of March 31, 2025, the Company had $9.7 million in cash and cash equivalents, compared to $3.2...

3M ago

DRMA

Optimistic Buy Rating for Dermata Therapeutics Driven by Promising Phase 3 Trial Results and Strong Financial Position

Analyst Anthony Vendetti of Maxim Group reiterated a Buy rating on Dermata Therapeutics (DRMA – Research Report), retaining...

4M ago

DRMA

Dermata Therapeutics files to sell 10.01M shares of common stock for holders

16:20 EDT Dermata Therapeutics (DRMA) files to sell 10.01M shares of common stock for holders Published first on...

4M ago

DRMA

Dermata’s XYNGARI trial hits statistically significant difference at 4 weeks

Dermata Therapeutics (DRMA) announced that additional analysis of topline data from its Phase 3 STAR-1 trial showed that...

4M ago

DRMA

DRMA FAQ

What was Dermata Therapeutics’s price range in the past 12 months?

Dermata Therapeutics lowest stock price was $5.73 and its highest was $30.74 in the past 12 months.

What is Dermata Therapeutics’s market cap?

Dermata Therapeutics’s market cap is $41.14M.

When is Dermata Therapeutics’s upcoming earnings report date?

Dermata Therapeutics’s upcoming earnings report date is Aug 07, 2025 which is tomorrow.

How were Dermata Therapeutics’s earnings last quarter?

Dermata Therapeutics released its earnings results on May 14, 2025. The company reported -$4.5 earnings per share for the quarter, the consensus estimate of -$4.5 by $0.

Is Dermata Therapeutics overvalued?

According to Wall Street analysts Dermata Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Dermata Therapeutics pay dividends?

Dermata Therapeutics does not currently pay dividends.

What is Dermata Therapeutics’s EPS estimate?

Dermata Therapeutics’s EPS estimate is -2.9.

How many shares outstanding does Dermata Therapeutics have?

Dermata Therapeutics has 6,378,118 shares outstanding.

What happened to Dermata Therapeutics’s price movement after its last earnings report?

Dermata Therapeutics reported an EPS of -$4.5 in its last earnings report, expectations of -$4.5. Following the earnings report the stock price went down -0.128%.

Which hedge fund is a major shareholder of Dermata Therapeutics?

Currently, no hedge funds are holding shares in DRMA

Dermata Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-206.26%

Trailing 12-Months

Asset Growth

93.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Dermata Therapeutics

Dermata Therapeutics, Inc. (DRMA) is a clinical-stage biotechnology company focused on developing and commercializing innovative pharmaceutical products for the treatment of medical and aesthetic skin conditions. The company operates in the biotechnology and pharmaceuticals sectors, leveraging its unique Spongilla technology platform to address unmet needs in dermatology.

Dermata Therapeutics (DRMA) Earnings & Revenues

DRMA Earnings Data >

DRMA Stock 12 Month Forecast

Average Price Target

$3.00

▼(-57.51%Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","631":"$631","159.25":"$159.3","316.5":"$316.5","473.75":"$473.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,159.25,316.5,473.75,631],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2023","6":"Aug<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.2,7.799999999999999,7.3999999999999995,6.999999999999999,6.6,6.199999999999999,5.799999999999999,5.3999999999999995,5,4.6,4.199999999999999,3.8,3.3999999999999995,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.2,7.799999999999999,7.3999999999999995,6.999999999999999,6.6,6.199999999999999,5.799999999999999,5.3999999999999995,5,4.6,4.199999999999999,3.8,3.3999999999999995,{"y":3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.2,7.799999999999999,7.3999999999999995,6.999999999999999,6.6,6.199999999999999,5.799999999999999,5.3999999999999995,5,4.6,4.199999999999999,3.8,3.3999999999999995,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":630.24,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.75,"date":1682899200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.5,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.62,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.12,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.88,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.25,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >